The next financials will show the positive consequences of the reduction in costs by one-two million dollars. You can expect a growth in revenues, another FDA approval which will accept that the the SiN material is equal to PEEK the current standard of care, but SiN is much stronger and can sustain in the body for a a longer period, no bacterial infection, ...
By the way the company has more cash than their market cap: $18m in cash versus $7m market cap!!!
News 
Market Data 
Discover 
